Press Releases
Recro Pharma to Report First Quarter 2019 Financial Results and Host Conference Call and Webcast on May 10, 2019
Recro Pharma Announces Six-Year Extension of License and Supply Agreement Between Teva and Recro Gainesville
Recro Pharma Announces Presentation of New Meta-Analysis for IV Meloxicam at the 44th Annual Regional Anesthesiology and Acute Pain Medicine Meeting
Recro Pharma Restructures Acute Care Segment While Continuing To Execute on Strong CDMO Segment Performance
Recro Pharma Appoints Arnaud Ajdler to Its Board of Directors
Recro Pharma Receives Complete Response Letter from the FDA for Intravenous Meloxicam
Recro Pharma to Host Educational Symposium on Pain Management Options in Total Joint Replacements at the American Academy of Orthopaedic Surgeons 2019 Annual Meeting
Recro Pharma Obtains $40.5 Million of Non-Dilutive Capital Through Expanded Credit Facility
Recro Pharma Announces Publication of Phase III IV Meloxicam Clinical Safety and Opioid Use Data in the Journal Clinical Pharmacology in Drug Development
